{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
uridine triacetate
to a specific field?
Status:
Possibly Marketed Outside US
Source:
BLA125752
(2022)
Source URL:
First approved in 2022
Source:
BLA125752
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
BLA125742
(2021)
Source URL:
First approved in 2021
Source:
BLA125742
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
BLA125742
(2021)
Source URL:
First approved in 2021
Source:
BLA125742
Source URL:
Class:
NUCLEIC ACID
Status:
Possibly Marketed Outside US
Source:
NCT04588480: Phase 4 Interventional Completed SARS-CoV-2 Infection
(2020)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
Ann Oncol. Mar 2008;19(3):520-6.: Phase 3 Human clinical trial Completed Stomach Neoplasms/mortality/surgery
Source URL:
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2020)
Source URL:
First approved in 2014
Source:
21 CFR 333E
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT03223194: Phase 1 Interventional Terminated Crigler-Najjar Syndrome
(2017)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
